Becton Dickinson Recalls Certain Infusion Pumps, Citing Issues With Cardinal Health's Syringes
Portfolio Pulse from Vandana Singh
Becton, Dickinson, And Company (BDX) is recalling its Alaris infusion pumps due to compatibility issues with Cardinal Health Inc's (CAH) Monoject syringes, as announced by the FDA. The recall is classified as Class I, indicating a risk of serious injury or death. The issue arose after Cardinal Health changed the dimensions of its Monoject syringes during rebranding. There have been 13 reported injuries but no deaths. BDX shares saw a slight decline of 0.15% to $237.89.
December 04, 2023 | 7:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Becton, Dickinson, And Company is recalling its Alaris infusion pumps due to issues with Cardinal Health's Monoject syringes, which could lead to serious injuries. The recall is serious and may impact the company's reputation and sales.
The Class I recall is the most serious type, indicating potential for serious injury or death, which could negatively affect BDX's stock price due to concerns over product safety, potential lawsuits, and decreased sales.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Cardinal Health's Monoject syringes are involved in a compatibility issue with BDX's Alaris infusion pumps, leading to a Class I recall by the FDA. This could potentially affect CAH's brand image and product trust.
While the recall is directly related to BDX's products, the issue stems from CAH's syringes. This association with a Class I recall could lead to negative perceptions of CAH's products, potentially affecting sales and stock price.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70